Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation presenting as pericardial effusion
In the evolving field of hematology and oncology, addressing acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is crucial. A recent study highlighting AML relapse as…
ASCO China Voice | Professor Jian Zhang: The First ADC Targeting Nectin-4, 9MW2821, Shows Promising Efficacy and Safety in Multiple Cancers
Editor's Note: Nectin-4 has emerged as a highly expressed adhesion molecule in various solid tumors, becoming a popular target in recent research. 9MW2821, developed using an internationally leading ADC development…
EHA Expert Interview | Professor Zhiming Li: Zanubrutinib Combined with CHOP Shows Superior Efficacy in Newly Diagnosed DLBCL Patients, Especially in the GCB Subtype
In the treatment of diffuse large B-cell lymphoma (DLBCL), the R-CHOP regimen has been a cornerstone, but enhancing its efficacy remains a significant challenge in the medical community. At the…
EASL Liver Cancer Summit | HNF1A Gene: Unlocking the “Key” to Hepatocellular Carcinoma Risk – Exclusive Interview with Professor Mohamed Abdel Samie
Hepatocellular carcinoma (HCC), one of the most lethal tumors globally, has long been a research hotspot due to its complex pathogenesis involving interactions between genetics, metabolism, and viral infections. Recently, at the 2025 EASL Liver Cancer Summit held in Paris, France, a study by Professor Mohamed Abdel Samie's team from the Department of Hepatology and Gastroenterology at the National Liver Institute, Menoufia University, Egypt, revealed the crucial role of the HNF1A genotype in HCC risk. Oncology Frontier invited Professor Mohamed Abdel Samie to discuss the potential value of this gene in HCC screening and the impact of metabolic factors. We look forward to future personalized treatment strategies targeting specific genotypes bringing new breakthroughs in the prevention and treatment of HCC.
EHA Expert Interview | Professors Huilai Zhang and Shiyong Zhou’s Team: Major Advances in Lymphoma Research
The 29th European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain, from June 13-16, 2024. As the largest international conference in the field of hematology in Europe,…
EHA Expert Interview | Professor Jie Jin: Zhejiang University’s Voice Resonates Internationally with GR1803 for RRMM
The 29th European Hematology Association (EHA) Annual Meeting took place from June 13-16, 2024, in Madrid, Spain. As Europe's largest international event in the field of hematology, the meeting attracts…
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer Editor's Note: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have brought transformative breakthroughs to…
